Calzada Ltd

ASX:CZD

Presentation to Annual General Meeting 14 November 2012

For

per

sona

l use

onl

y

Disclaimer

This presentation is provided for general information purposes only. It is not intended to

be relied upon as advice and does not take into account the investment objectives,

financial situation or needs of any particular investor. Whilst Calzada Limited has taken

all reasonable measures to ensure that the material contained in this newsletter is

correct, Calzada Limited does not give any warranty or representation as to the

accuracy, reliability or completeness of the information. Specifically, we note that

several of the items here are still under investigation and are subject to change or even

elimination, depending on further research and investigation. To the extent permitted by

law, neither Calzada Limited nor any of its related bodies corporate or their respective

officers or employees will be liable in any way for any loss, damage, cost or expenses

suffered or incurred by any person relying on the information contained in this

presentation or in connection with the provision of contents of this presentation.

For

per

sona

l use

onl

y

For

per

sona

l use

onl

y

Key Achievements Low cost out-licensing strategy to generate value

Metabolic’s costs running at approx 10% of total CZD after tax costs

• Invented new applications for AOD9604 in muscle & cartilage – Mt Sinai Hospital testing showed that AOD has the potential repair

muscle and cartilage

– Contracted a Korean group to test AOD in a collagenase-induced osteoarthritis model in a rabbit. Results due early 2013.

– AOD may have application in a range of musculoskeletal disorders including joint disease

– New patent filed to protect this discovery

– May be possible to commence clinical development at phase 2

– Potential human and veterinary applications

• Achieved GRAS status in the US, conditional on publication of existing safety data

For

per

sona

l use

onl

y

Progress advancing AOD9604 • Updated Manufacturing Plan and working closely with one company

to be ready for market scale production

• Veterinary Applications – Two large vet companies have shown some early stage interest in AOD – Looking at conducting a trial in thoroughbreds for shin soreness and leg

injuries – Talked to other interested groups involved with Stem cells and obese dogs

• Human Pharmaceutical – One large company completed due diligence on the osteoporosis application

but declined to proceed – One large device company has asked to look at the bone biologic data with the

aim of enhancing bone formation – Considering clinical trial opportunities in AU and overseas for weight

management and joint disease – US CDC - Lifetime risk of OA is 45% but for obese it is 66% and 50% for Diabetics

For

per

sona

l use

onl

y

Progress advancing AOD9604

• Human GRAS status

– Conditional on publication

– Two papers on existing safety data recently prepared

– Papers currently being submitted to journals

– Publication expected Q1/Q2 2013

– Publication will remove the condition on the GRAS enabling AOD to be added to foods, drinks & dietary supplements in the US market

– Exploring EU options including a novel food application

For

per

sona

l use

onl

y

Summary

• Aim to rapidly confirm that AOD9604 has substantial potential

commercial value

• Continue a low cost out-licensing strategy to generate shareholder

wealth by exploring high potential opportunities for AOD9604 in:

– Human pharmaceuticals – joint disease and if possible weight loss

– Veterinary applications - obesity and musculoskeletal disease; and

– GRAS foods, drinks & dietary supplements in the US

• Consider human clinical trial options to speed development and to

significantly enhance value

For

per

sona

l use

onl

y

For

per

sona

l use

onl

y

Negative Pressure Wound Therapy Dressing

Background • Around mid 2010, PolyNovo started to work on the development of a Negative Wound Pressure Therapy dressing,

this product is designed to overcome the infection issue described in the FDA Preliminary Public Health Notification dated 23, November 2009 (updated in February 2011)

• The NPWT dressing market is estimated at $500 million per year and is increasing steadily year on year

Goals • Develop a product with a better biological safety profile

• Improve patient outcome and reduce infection risk

• Have a market ready product in 2013

Regulatory strategy • Concentrate efforts on 510 k) application for the US market

– Predicate device includes GranufoamTM

– Lodge 510 k) application as soon as possible (clinical trial results not required)

– Obtain marketing authorisation in 2013

• CE mark application during 2013

– Prepare technical file (Class 2B device)

– Achieve ISO 13485 accreditation (scope to include medical device manufacturing)

For

per

sona

l use

onl

y

Negative Pressure Wound Therapy Dressing

Clinical trial Status

• 15 patients enrolled: 10 completed treatment, 2 withdrawn ( one in each group), 3 currently in treatment

• NovoSorb Vac dressings perform as expected

Commercial strategy • Publish clinical data to support commercial activities

• Select a partner for distribution or licencing agreement in 2013

• Generate revenue through product manufacturing and royalties

For

per

sona

l use

onl

y

Biodegradable Temporising Matrix BTM

Background • BTM project was given highest priority in the new strategic plan formulated in 2010, in order to achieve a First in

Man event within 2 years. Following the award of a BioSA grant in July 2010, the device development and pre-clinical activities commenced

• The BTM is designed to provide a best in class alternative to existing dermal replacement devices for third degree burns

• The market size for dermal replacement device is currently estimated at $200 million

Goals • Develop a synthetic product to overcome the issues associated with collagen based products • Improve patient outcome • Reduce third degree burn treatment cost • Achieve first in man use of the NovoSorb technology • Have a market ready product in 2013/2014

Regulatory strategy • CE mark application for the European Market

– Prepare Design Dossier (Class 3 device) – Achieve ISO 13485 accreditation (scope to include medical device manufacturing) – Evaluate clinical trial requirements after Free Flap trial completion

For

per

sona

l use

onl

y

Biodegradable Temporising Matrix BTM

• US market – Third degree burn treatment requires PMA – IDE required to commence clinical trial – Prepare first IDE (2012) for Feasibility Trial in 2013 – Obtain PMA in 2014 – Evaluate 510k) application for full thickness surgical wounds and deep dermal burns requiring skin graft

• Predicate device includes IntegraTM

• If 510 k) is an option, have a product ready in 2013

Clinical trial Status • 4 patients enrolled: 4 completed treatment • NovoSorbTM BTMs perform as expected

Further Clinical trials • HREC application for Burn trial lodged (decision 15 November) • Received positive feedback from KOLs to participate in pivotal trial including US, France, Japan • Started dialogue with the FDA regarding US trial

F

or p

erso

nal u

se o

nly

Biodegradable Temporising Matrix BTM

Commercial strategy • Publish clinical data to support commercial activities

• Validate device manufacturing processes

• Continue dialogue with KOL’s in Europe and US

• Small concentrated market reduces reliance on distributor for BTM, offering the possibility for NovoSkin to market product independently

• Finalise commercial strategy by H1 2012

For

per

sona

l use

onl

y

Smith and Nephew license

• PolyNovo continues to work with Smith and Nephew to develop products in

the Bone Void Filler and Fracture Fixation fields

• Supply of testing material for the DARPA project generated small revenue in 2012 (US$120,000)

• Device developments are driven by Smith and Nephew

For

per

sona

l use

onl

y

PolyNovo Key Achievements

• Developed a NovoSorbTM scaffold with utility in multiple medical device applications

• Developed and optimised BTM for full thickness burns • “First in Man” event with 2 clinical trials currently

underway • Established relationship with KOLs • Demonstrated PolyNovo’s ability to deliver on its

strategy • Cultured Composite Skin (“ Artificial skin”) proof of

concept achieved, demonstrating NovoSorbTM scaffold utility in Tissue Engineering applications

For

per

sona

l use

onl

y